Condition: HER2+ Metastatic Breast Cancer · Sponsor: Duke University
The purpose of this study is to evaluate the intracranial response rate of a combination of asciminib/trastuzumab for the treatment of patients with metastatic HER2+ breast cancer with brain metastases.
This description comes directly from the study's public registry record.
Carey Anders, MD · 919-471-8344 · carey.anders@duke.edu
Breast Clinic · 919-660-1278 · breastcl@dm.duke.edu
Always discuss trial participation with your own doctor first.
| Duke University | Durham, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07136428